Trial Profile

Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 15 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ibrutinib (Primary)
Indications B-cell lymphoma; CNS cancer; Intraocular lymphoma; Lymphomatous meningitis; Non-Hodgkin's lymphoma
Focus Proof of concept; Therapeutic Use
Acronyms iLOC

Most Recent Events

06 Apr 2022 Status changed from active, no longer recruiting to completed.
30 Mar 2021 Planned End Date changed from 1 Jan 2021 to 1 Jan 2022.
03 Jul 2019 Results published in the European Journal of Cancer

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com